Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodium falciparum circumsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines.

Original publication

DOI

10.1016/j.vaccine.2006.06.022

Type

Journal article

Journal

Vaccine

Publication Date

30/10/2006

Volume

24

Pages

6526 - 6533

Keywords

Adult, Animals, Antibodies, Protozoan, Antibody Specificity, Cross Reactions, Dose-Response Relationship, Immunologic, Enzyme-Linked Immunosorbent Assay, Gambia, Humans, Immunity, Cellular, Immunization, Secondary, Immunoglobulin G, Interferon-gamma, Malaria Vaccines, Malaria, Falciparum, Male, Phenotype, Plasmodium falciparum, T-Lymphocytes